drugset / Trial / NCT03928379

A Study of LY3305677 in Participants With Type 2 Diabetes

NCT03928379

Phase 1 Completed 24 enrolled Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes. The study will last about 20 weeks for each participant, not including screening.

Timeline

Start
2019-10-27
Primary completion
2021-07-08
Completion
2021-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mazdutide Protein / enzyme biologic Subcutaneous